V118E Vaccine for Pneumococcal Disease Prevention
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new vaccine, V118E, to prevent diseases caused by Streptococcus pneumoniae, a bacterium with many varieties. The trial compares V118E with an existing vaccine, PREVNAR 20™, to assess safety and tolerance. Participants will receive two doses of either V118E or PREVNAR 20™ with saline. Healthy adults without serious infections from these bacteria in the past three years may qualify for this trial. As a Phase 1 trial, this research aims to understand how the new vaccine works in people, offering participants the chance to be among the first to receive this innovative treatment.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that the V118E vaccine is likely to be safe for humans?
Research has shown that current pneumococcal vaccines, such as PREVNAR 20™, are safe and typically cause no serious side effects. Although specific safety data for the new V118E vaccine is not yet available, it is currently undergoing testing in a phase 1 study. Researchers are primarily assessing its safety and tolerability in people. As this is an early-stage study, detailed safety information for V118E may not yet be available. However, since it is being compared to PREVNAR 20™, researchers hope it will exhibit a similar safety profile.12345
Why do researchers think this study treatment might be promising?
The V118E vaccine is unique because it uses a new formulation designed to enhance immune response against pneumococcal disease. Unlike standard vaccines like PREVNAR 20™, which are typically given in a single dose regimen, V118E is administered in a 2-dose regimen. This approach may offer stronger or longer-lasting protection. Researchers are excited about V118E because it could potentially provide more effective prevention of pneumococcal infections, which are a major cause of illnesses like pneumonia and meningitis.
What evidence suggests that the V118E vaccine might be an effective treatment for pneumococcal disease?
Research has shown that vaccines like V118E are designed to prevent diseases caused by the Streptococcus pneumoniae bacteria. In this trial, participants will receive either the V118E vaccine or PREVNAR 20™ in separate treatment arms. The V118E vaccine helps the body produce antibodies, proteins that combat infections, against specific types of these bacteria. Earlier vaccines for similar bacteria have proven 50% to 80% effective in preventing serious illnesses. These results suggest that V118E could provide strong protection against pneumococcal disease by enabling the immune system to fight infections effectively.16789
Who Is on the Research Team?
Medical Director
Principal Investigator
Merck Sharp & Dohme LLC
Are You a Good Fit for This Trial?
This trial is for healthy adults who are in good health before being randomly assigned to a group. There's no list of specific exclusions provided, so generally, people with underlying health conditions or those taking certain medications may not be eligible.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive intramuscular (IM) injection of V118E in a 2-dose regimen administered on Day 1 and Day 29
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- V118E
Trial Overview
The study is testing the safety and tolerability of a new vaccine called V118E designed to prevent diseases caused by Streptococcus pneumoniae bacteria. It will be compared against PREVNAR 20™ and saline (a placebo).
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Participants receive intramuscular (IM) injection of V118E in a 2-dose regimen administered on Day 1 and Day 29.
Participants receive one dose of IM injection of PREVNAR 20™ in a 2-dose regimen on Day 1 followed by one dose of saline on Day 29.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Merck Sharp & Dohme LLC
Lead Sponsor
Chirfi Guindo
Merck Sharp & Dohme LLC
Chief Marketing Officer since 2022
Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business
Robert M. Davis
Merck Sharp & Dohme LLC
Chief Executive Officer since 2021
JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University
Citations
NCT07168915 | A Study of V118E in Healthy Participants ...
Researchers designed a new vaccine, V118E, to help prevent disease from Streptococcus pneumoniae bacteria. The goal of this study is to learn how safe V118 ...
Pneumococcal Vaccine - StatPearls - NCBI Bookshelf
The Center for Disease Control (CDC) and Advisor Committee on Immunization ... It has shown a 50% to 80% efficacy in preventing invasive pneumococcal disease in ...
Real world effectiveness of antipneumococcal vaccination ...
As main finding in this real-world data study, pneumococcal vaccination did not prove effective (neither PPsV23 nor PCV13) in preventing ...
Systematic Review and Meta-Analysis of the Efficacy ...
Only one RCT (CAPITA) was identified, with a reported efficacy of 75% (95% CI: 41%, 91%) against PCV13-type IPD in Dutch pneumococcal vaccine-naïve, community- ...
Pneumococcal Disease Prevention: Are We on the Right ...
Moreover, the new PCVs showed little effectiveness in the prevention of infection due to non-encapsulated STs and to ST3. Next-generation S. pneumoniae vaccines ...
Safety and Immunogenicity of V118E Vaccine in Healthy ...
The study aims to see how safe this new vaccine is and how well healthy adults can tolerate it. This research is important because it could lead ...
V118E Vaccine for Pneumococcal Disease Prevention
The goal of this study is to learn how safe V118 formulation E is in Healthy Adults and how well people tolerate it.
Pneumococcal Vaccine Safety
A closer look at the safety data · A 2004 study of VAERS data found that most adverse events reported during the first two years after licensure ...
Post-marketing safety surveillance of pneumococcal vaccines
Current pharmacovigilance data demonstrate well-established safety profiles in adolescent and adult populations receiving these immunizations.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.